Bank of America Corp DE Sells 36,093 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Bank of America Corp DE reduced its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 29.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 86,096 shares of the specialty pharmaceutical company's stock after selling 36,093 shares during the quarter. Bank of America Corp DE owned 0.27% of Collegium Pharmaceutical worth $2,467,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. New Age Alpha Advisors LLC bought a new stake in shares of Collegium Pharmaceutical during the 4th quarter worth $40,000. KBC Group NV lifted its position in shares of Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after buying an additional 982 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Collegium Pharmaceutical by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after buying an additional 642 shares during the last quarter. Aigen Investment Management LP bought a new stake in shares of Collegium Pharmaceutical during the 4th quarter worth $230,000. Finally, Summit Global Investments bought a new stake in shares of Collegium Pharmaceutical during the 4th quarter worth $232,000.

Analysts Set New Price Targets

Several analysts recently weighed in on COLL shares. Needham & Company LLC restated a "buy" rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Wall Street Zen downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. Piper Sandler reiterated a "neutral" rating and issued a $37.00 target price (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Finally, HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $43.80.

Collegium Pharmaceutical Trading Up 0.3%

Collegium Pharmaceutical stock traded up $0.10 during trading hours on Thursday, hitting $29.50. The stock had a trading volume of 159,175 shares, compared to its average volume of 418,351. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The stock has a market cap of $947.89 million, a price-to-earnings ratio of 12.72 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a one year low of $23.23 and a one year high of $42.29. The business's 50 day simple moving average is $27.98 and its 200-day simple moving average is $29.59.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $177.76 million for the quarter, compared to the consensus estimate of $174.96 million. During the same quarter last year, the business earned $1.45 earnings per share. Collegium Pharmaceutical's revenue was up 22.7% compared to the same quarter last year. On average, equities analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 2,255 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the sale, the executive vice president now directly owns 124,421 shares in the company, valued at approximately $3,732,630. The trade was a 1.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Colleen Tupper sold 977 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the sale, the chief financial officer now owns 164,269 shares of the company's stock, valued at approximately $4,928,070. The trade was a 0.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,677 shares of company stock worth $410,414 over the last ninety days. 2.51% of the stock is owned by insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.